Understanding the Relationship Between Germ Layer Origin and Cancer Therapy Response: A Systematic Review

Author: David Ferguson 1,2

1 Virginia Peninsula Community College, Hampton, VA

2 Howard University, Washington, DC, USA

Abstract

Background: Cancer therapeutic response patterns may be fundamentally influenced by embryonic germ layer origin. Emerging evidence suggests mesoderm-derived malignancies exhibit exceptional responsiveness to cellular immunotherapy, endoderm-derived epithelial cancers demonstrate marked sensitivity to protein signaling inhibitors, and ectoderm-derived tumors show heightened immunogenicity enabling breakthrough responses to checkpoint blockade and messenger RNA vaccine strategies.

Methods: We conducted a systematic review following PRISMA 2020 guidelines. PubMed/MEDLINE, Embase, and Web of Science were searched from inception through 13 October 2025 using predefined PICOS criteria and a reproducible search strategy. A prespecified protocol (archived; no prior registry) guided screening, data extraction, and risk-of-bias assessment.

Eligibility: We included patients with malignancies assignable to ectoderm, mesoderm, or endoderm lineages receiving cellular immunotherapies, protein-targeted agents/antibody-drug conjugates, or nucleic acid/immunomodulatory therapies. Eligible comparators included active controls, standard care, placebo, or single-arm designs where appropriate. Study designs comprised randomized controlled trials, non-randomized comparative studies, and pivotal single-arm trials in refractory settings. We excluded preclinical studies, case reports/series with fewer than ten patients, studies without extractable endpoints, duplicate/superseded publications, and cancers with unassignable lineage.

Outcomes and Analysis: Primary outcomes were objective response rate, progression-free survival, and overall survival. Secondary outcomes included complete response, duration of response, event-free/recurrence-free survival, and safety. Effect measures were hazard ratios for time-to-event data and risk/odds ratios for binary outcomes. Random-effects meta-analysis

was planned for clinically and statistically homogeneous subsets; otherwise, we performed SWiM-compliant narrative synthesis with megatrend analysis given extreme clinical heterogeneity. Evidence synthesis incorporated National Comprehensive Cancer Network Clinical Practice Guidelines, American Society of Clinical Oncology publications, American Cancer Society statistics, and landmark phase III/IV clinical trials.

Verification: Clinical outcome data underwent triple-checking using independent search strategies. Large language model tools assisted with abstract screening prioritization only; all eligibility assessment, data extraction, risk-of-bias evaluation, and synthesis were performed exclusively by human reviewers.

Findings: Three major megatrends emerged. First, mesoderm-derived hematologic malignancies achieved complete response rates of 82-97% with chimeric antigen receptor T-cell therapies across multiple pivotal trials. Second, endoderm-derived adenocarcinomas demonstrated consistent vulnerability to targeted therapies, with median overall survival of 19-47 months when treated with matched protein pathway inhibitors. Third, ectoderm-derived melanoma exhibited sustained immune control, with checkpoint blockade achieving 43% ten-year overall survival in advanced disease and personalized messenger RNA neoantigen vaccines providing 49% risk reduction for recurrence in the adjuvant setting.

Interpretation: Embryonic germ layer origin provides valuable exploratory context for understanding cancer therapeutic response patterns. This developmental framework complements molecular biomarker-driven precision oncology and may inform treatment selection, clinical trial design, and drug development prioritization.

Keywords: Embryonic germ layers, developmental biology, cancer therapy, CAR-T cells, targeted therapy, immunotherapy, tissue of origin, systematic review

Introduction

The Developmental Blueprint of Cancer

The relationship between cancer and development represents one of oncology's most profound conceptual connections (Gilbert, 2016; Friedmann-Morvinski & Verma, 2016). During embryonic gastrulation, the specification of three primary germ layers establishes the architectural foundation for all subsequent tissue formation. This trilaminar organization is not merely transient embryonic anatomy but rather represents fundamental cellular commitments that persist throughout organismal life and can be reactivated in malignancy (Tam & Behringer, 1997).

The Cancer Genome Atlas Pan-Cancer Atlas initiative provided compelling support for the cell of origin paradigm through comprehensive molecular characterization of over twenty thousand tumors (Hoadley et al., 2018). When researchers performed unsupervised clustering using

integrated data, tumors predominantly grouped by histology and tissue type rather than by shared oncogenic driver mutations, demonstrating that developmental lineage often proves more deterministic of tumor core identity than subsequently acquired somatic mutations (Hoadley et al., 2018).

Rationale for a Germ Layer Framework

The differential success of modern therapeutic modalities across cancer types, coupled with established primacy of developmental lineage in defining tumor identity, raises a compelling hypothesis: can the fundamental divisions of embryonic germ layers provide a unifying framework for understanding therapeutic response patterns? This systematic review synthesizes contemporary evidence to explore these relationships, proposing that mesoderm-derived cancers exhibit enhanced responsiveness to cellular immunotherapies, endoderm-derived cancers demonstrate inherent vulnerabilities to protein signaling pathway inhibition, and ectoderm-derived cancers show particular promise with nucleic acid-based interventions and immunomodulation.

Methods

Search Strategy and Verification Methodology

We conducted this systematic review according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines (Page et al., 2021). A comprehensive literature search was performed across PubMed/MEDLINE, Embase, and Web of Science Core Collection from database inception through October 2025. PubMed/MEDLINE, Embase (Ovid), and Web of Science Core Collection through **13 Oct 2025**, plus ClinicalTrials.gov and major guideline repositories for context. Reference lists of included studies and relevant reviews were snowballed. Full, line-by-line database strategies as run (with dates/filters) are reproduced in **Supplement 2** to enable replication.Titles/abstracts and full texts were screened by one reviewer (D.J.F.) using a piloted form; reasons for exclusion at full-text are logged in **Supplement 3**. To mitigate selection bias, we applied calibration on an initial set and maintained a decision rulebook.Data extraction was performed by one reviewer using a standardized form (Supplement 4) capturing design, population, lineage mapping, interventions, outcomes, and effect estimates. **Risk of bias:** RCTs—Cochrane RoB 2; non-randomized—ROBINS-I. Judgments with rationale are in **Supplement 5**.Random-effects meta-analysis (HKSJ/REML) was planned when ≥3 studies were clinically and statistically commensurate; heterogeneity (I^2, τ^2) and small-study effects (Egger/Harbord) were assessed where applicable. Otherwise, we followed **SWiM** guidance for structured narrative synthesis, grouping by **(germ layer → modality)**. Certainty of evidence was appraised with **GRADE** and summarized in **Summary-of-Findings** tables (Supplement 6).

Verification Methodology with Large Language Model Integration: Large-language-model tools were used only to prioritize citations for manual screening. All inclusion decisions, data extraction, risk-of-bias assessments, and synthesis were performed by the author. No text or

quantitative results were accepted without human verification.During initial screening of 4,542 unique records, advanced artificial intelligence tools assisted with high-volume abstract review to prioritize potentially relevant records based on predefined inclusion criteria. The large language model prompts employed were: "Identify clinical trials and reviews examining cancer therapy response by tissue origin, germ layer, or developmental lineage. Flag studies reporting objective response rates, progression-free survival, or overall survival for cellular immunotherapy, targeted protein inhibitors, or nucleic acid-based therapies." This preliminary screening generated candidate articles for human review. However, to ensure rigor and accuracy, all subsequent stages including final eligibility assessment, critical appraisal, data extraction, and synthesis were conducted exclusively by a human reviewer. Clinical trial data was triple-checked using three independent verification strategies: cross-referencing ClinicalTrials.gov registries with primary journal publications, confirming efficacy parameters across conference presentations and regulatory documents, and validating statistics through manufacturer prescribing information where applicable.

Germ Layer Classification and Data Extraction

Major cancer types were systematically classified according to primary embryonic germ layer origin based on canonical developmental biology principles and insights from large-scale genomic analyses (Hoadley et al., 2018). Mesoderm-derived cancers included hematologic malignancies, sarcomas, and renal cell carcinoma. Endoderm-derived cancers encompassed adenocarcinomas of lung, gastrointestinal tract, liver, and pancreas. Ectoderm-derived cancers included melanoma, glioblastoma, squamous cell carcinomas, and breast cancer.

We extracted data identifying therapeutic response patterns corresponding to three predefined modality classes: cellular immunotherapy, protein-targeted agents, and nucleic acid-based interventions. Given extreme clinical and methodological heterogeneity, formal meta-analysis was deemed inappropriate. We therefore performed rigorous narrative synthesis allowing detailed exploration of relationships between germ layer origin and therapy response (Guyatt et al., 2008).

Quality Assessment

Evidence quality was evaluated using principles derived from Grading of Recommendations Assessment, Development and Evaluations methodology. We assessed study design quality, consistency of findings across multiple investigations, directness of evidence, and risk of bias within landmark trials using Cochrane Risk of Bias 2 tool for randomized studies and ROBINS-I for non-randomized investigations (Sterne et al., 2019).

Megatrend One - Mesoderm-Derived Malignancies and Cellular Immunotherapy Synergy

Unprecedented Efficacy in Hematologic Malignancies

The analysis provides robust support for exceptional sensitivity of mesoderm-derived hematologic malignancies to cellular immunotherapies (Zelenetz et al., 2023; Kumar et al., 2023). Landmark chimeric antigen receptor T-cell therapy trials have produced unprecedented efficacy establishing new treatment paradigms (NCCN, 2023a; NCCN, 2024a).

In the pivotal ELIANA trial, tisagenlecleucel targeting CD19 induced overall remission rates of eighty-one percent in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia, with sustained responses at three-year follow-up (Maude et al., 2018; Laetsch et al., 2023). The initial analysis demonstrated that among seventy-five infused patients, sixty-one achieved complete remission or complete remission with incomplete hematologic recovery within three months, with all responders achieving minimal residual disease negativity by flow cytometry (Maude et al., 2018). At median follow-up of thirty-eight point eight months, event-free survival reached forty-four percent and overall survival reached sixty-three percent at three years, with most events occurring within the first two years (Laetsch et al., 2023). These outcomes in heavily pretreated pediatric patients with poor prognosis represented a transformative advance, leading to Food and Drug Administration approval and incorporation into National Comprehensive Cancer Network Acute Lymphoblastic Leukemia Guidelines Version 2.2024 as a preferred option for relapsed or refractory disease (NCCN, 2024b; Brown et al., 2024).

The ZUMA-1 trial of axicabtagene ciloleucel in refractory large B-cell lymphoma reported objective response rates of eighty-two percent with complete response rates of fifty-eight percent, demonstrating curative potential in heavily pretreated patients (Neelapu et al., 2017). Five-year follow-up data confirmed durability, with forty-three percent of patients remaining progression-free and forty-two percent alive at five years post-infusion, supporting curative potential (Locke et al., 2023). The ZUMA-7 phase 3 trial elevated axicabtagene ciloleucel to second-line therapy by demonstrating superior overall survival compared to standard care in patients with early relapsed large B-cell lymphoma, fundamentally changing treatment paradigms (Locke et al., 2022; Westin et al., 2023). Current National Comprehensive Cancer Network B-Cell Lymphomas Guidelines Version 3.2025 incorporate chimeric antigen receptor T-cell therapy as preferred options for diffuse large B-cell lymphoma in second-line and subsequent settings based on this evidence (NCCN, 2025a; Zelenetz et al., 2023).

In multiple myeloma, CARTITUDE-1 trial results for ciltacabtagene autoleucel targeting B-cell maturation antigen demonstrated remarkable ninety-seven point nine percent overall response rates with eighty-two point five percent stringent complete responses in patients who had exhausted multiple prior therapy lines (Berdeja et al., 2021; Martin et al., 2023). At median follow-up of twenty-seven point seven months, median duration of response was not reached, and median overall survival exceeded forty-one point nine months (Martin et al., 2023). Long-term follow-up at median sixty-one point three months revealed that one-third of patients remained alive and progression-free for at least five years after a single infusion, with all assessed patients maintaining minimal residual disease negativity and positron emission tomography-computed tomography negativity (Jagannath et al., 2025). The phase 3 CARTITUDE-4 trial definitively established ciltacabtagene autoleucel superiority over standard care in lenalidomide-refractory multiple myeloma with one to three prior lines, demonstrating

significantly prolonged progression-free survival (San-Miguel et al., 2023). National Comprehensive Cancer Network Multiple Myeloma Guidelines Version 2.2026 now include chimeric antigen receptor T-cell therapy and bispecific antibodies as preferred options for relapsed or refractory disease after appropriate prior therapies, reflecting the transformative impact of cellular immunotherapy (NCCN, 2026a; Kumar et al., 2023).

The KarMMa trial of idecabtagene vicleucel in relapsed or refractory multiple myeloma achieved seventy-three percent overall response rate with thirty-three percent complete response, while the phase 3 KarMMa-3 trial demonstrated significant progression-free survival improvement compared to standard regimens in triple-class-exposed patients (Munshi et al., 2021; Rodriguez-Otero et al., 2023). TRANSCEND NHL 001 demonstrated lisocabtagene maraleucel efficacy in large B-cell lymphoma with seventy-three percent objective response rate and fifty-three percent complete response in the primary efficacy population (Abramson et al., 2020). The phase 3 TRANSFORM trial established lisocabtagene maraleucel superiority in second-line large B-cell lymphoma with eighty percent overall response rate and fifty-four point one percent complete response versus forty-eight percent and twenty-one percent respectively with standard salvage therapy (Kamdar et al., 2022).

American Cancer Society statistics reveal the scale of impact (Siegel et al., 2024). Cancer Facts and Figures 2024 projects sixty-two thousand seven hundred seventy new leukemia cases with seventy percent five-year survival, eighty thousand three hundred fifty new non-Hodgkin lymphoma cases with seventy-four percent five-year survival, and thirty-five thousand seven hundred eighty new multiple myeloma cases with fifty-nine point eight percent five-year survival (Siegel et al., 2024). These survival gains occurred rapidly following approvals of tisagenlecleucel, axicabtagene ciloleucel, and subsequent chimeric antigen receptor products. Childhood acute lymphoblastic leukemia now achieves approximately ninety percent five-year survival, while Hodgkin lymphoma reaches ninety-three to ninety-five percent depending on stage, representing some of the most curable cancer types (American Cancer Society, 2024a; American Cancer Society, 2024b).

American Society of Clinical Oncology publications document the cellular immunotherapy revolution in hematologic malignancies (Neelapu, 2023; Shah & Fry, 2019). The Journal of Clinical Oncology educational series on chimeric antigen receptor T-cell therapy mechanisms, toxicity management, and clinical applications provides comprehensive guidance for practitioners (June & Sadelain, 2018; Maude et al., 2023). Reviews trace development from concept through regulatory approval, highlighting response rates that exceed eighty percent in appropriate patient populations (Sterner & Sterner, 2021). Practice guidelines address cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome management, critical for safe delivery (Santomasso et al., 2021; ASCO, 2023). The American Society of Hematology Educational Program includes annual updates on cellular therapy advances in multiple myeloma, lymphoma, and leukemia, synthesizing evidence for clinical decision-making (ASH, 2024).

Mechanistic Basis: Developmental Synergy

The superior efficacy of cellular immunotherapy in mesodermal hematologic malignancies reflects fundamental biological and architectural features (June & Sadelain, 2018). Circulating malignant cells in blood and bone marrow provide direct physical access for intravenously infused engineered T-cells, circumventing formidable challenges of infiltration into dense, fibrotic, poorly vascularized tumor microenvironments characteristic of many solid tumors (Marofi et al., 2021). Beyond accessibility, shared mesodermal origin of T-cells and B-cell targets likely fosters developmental synergy. Both cell types arise from hematopoietic stem cells and operate within identical biological contexts of lymphoid organs and bone marrow, implying use of common molecular toolkits including matched adhesion molecules and chemokine receptors guiding trafficking and facilitating cell-cell interactions (June et al., 2018).

Challenges in Solid Mesodermal Tumors

Application of cellular therapies to solid tumors of mesodermal origin has proven more challenging, underscoring significant barriers posed by solid tumor microenvironments even within the same germ layer (Marofi et al., 2021). In sarcomas, engineered T-cell receptor therapies targeting cancer-testis antigens showed promising signals, with recent approval of afamitresgene autoleucel for MAGE-A4 expressing synovial sarcoma achieving forty-three percent objective response rates in heavily pretreated patients (Ramachandran et al., 2023). National Comprehensive Cancer Network Soft Tissue Sarcoma Guidelines Version 2.2024 now include afamitresgene autoleucel as an option for advanced synovial sarcoma with appropriate human leukocyte antigen typing (NCCN, 2024c).

In renal cell carcinoma, feasibility of isolating and expanding functional tumor-infiltrating lymphocytes has been demonstrated with expanded cells showing reactivity against autologous tumors (Seitter et al., 2021). However, clinical efficacy data remain preliminary. National Comprehensive Cancer Network Kidney Cancer Guidelines Version 1.2026 primarily emphasize immune checkpoint inhibitor plus tyrosine kinase inhibitor combinations rather than cellular therapy, reflecting current evidence limitations (NCCN, 2026b).

Megatrend Two - Endoderm-Derived Neoplasms and Protein Signaling Dependency

Precision Targeting of Oncogenic Signaling in Epithelial Cancers

Cancers arising from endoderm, which forms specialized epithelial linings of gastrointestinal and respiratory tracts, frequently exhibit profound dependencies on protein signaling pathways essential for their normal epithelial function (Ettinger et al., 2024; NCCN, 2024d). Therapies precisely inhibiting these hijacked pathways have become treatment cornerstones across multiple malignancies (Chaft et al., 2024; Ettinger et al., 2022).

In lung adenocarcinoma, profound dependency on epidermal growth factor receptor signaling is highlighted by tyrosine kinase inhibitor success. The FLAURA2 trial demonstrated that first-line osimertinib plus chemotherapy achieved median progression-free survival of twenty-five point

five months compared with sixteen point seven months for osimertinib monotherapy in patients with EGFR-mutated non-small cell lung cancer, representing a significant thirty-eight percent reduction in risk of disease progression or death (Planchard et al., 2023). Updated overall survival analysis with median follow-up of fifty-one point three months revealed median overall survival of forty-seven point five months with the combination versus thirty-seven point six months with monotherapy, confirming osimertinib plus chemotherapy as first-line standard of care (Planchard et al., 2025). The FLAURA trial previously established osimertinib superiority over first-generation EGFR tyrosine kinase inhibitors gefitinib or erlotinib, demonstrating median overall survival of thirty-eight point six months versus thirty-one point eight months and establishing osimertinib as preferred monotherapy (Ramalingam et al., 2020). The ADAURA trial further demonstrated osimertinib benefit in adjuvant settings for resected early-stage disease, reducing disease-free survival events by eighty-three percent compared with placebo (Herbst et al., 2023). National Comprehensive Cancer Network Non-Small Cell Lung Cancer Guidelines Version 8.2025 incorporate osimertinib prominently across treatment stages, including combination with chemotherapy as preferred first-line for EGFR-mutated advanced disease and adjuvant monotherapy for resected stage IB to IIIA disease (NCCN, 2025b; Ettinger et al., 2024).

In gastric cancer, HER2-directed antibody-drug conjugates transformed treatment outcomes. The DESTINY-Gastric04 phase 3 trial established trastuzumab deruxtecan as second-line standard of care, demonstrating median overall survival of fourteen point seven months compared with eleven point four months for ramucirumab plus paclitaxel in HER2-positive gastric or gastroesophageal junction adenocarcinoma, representing thirty percent reduction in death risk (Shitara et al., 2025). The trial enrolled four hundred ninety-four patients with metastatic or unresectable disease that progressed during or after trastuzumab-based first-line therapy. Objective response rate reached forty-four point three percent with trastuzumab deruxtecan versus twenty-nine point one percent with standard therapy, while disease control rate achieved ninety-one point nine percent versus seventy-five point nine percent (Shitara et al., 2025). This success built upon DESTINY-Gastric01 phase 2 trial demonstrating fifty-one percent objective response rate versus fourteen percent with chemotherapy and median overall survival of twelve point five months versus eight point four months in previously treated patients (Shitara et al., 2020). National Comprehensive Cancer Network Gastric Cancer Guidelines Version 3.2025 now include trastuzumab deruxtecan as preferred option for HER2-positive disease after prior trastuzumab-containing therapy, reflecting transformative impact of antibody-drug conjugates in endoderm-derived malignancies (NCCN, 2025c; Ajani et al., 2024).

Convergence of Anti-Angiogenic and Immunotherapeutic Strategies

The IMbrave150 trial provides compelling evidence for synergistic combination strategies exploiting multiple biological vulnerabilities of endoderm-derived hepatocellular carcinoma (Finn et al., 2020). This phase 3 study established atezolizumab plus bevacizumab as first-line standard for unresectable hepatocellular carcinoma, demonstrating superior median overall survival of nineteen point two months compared with thirteen point four months for sorafenib, with hazard ratio of zero point five eight (Finn et al., 2020). Updated analysis with median

follow-up of fifteen point six months confirmed progression-free survival benefit with median of six point eight months versus four point three months, hazard ratio zero point five nine (Finn et al., 2022). The combination leverages hepatocellular carcinoma's characteristic high vascularity targeted by bevacizumab while addressing immunosuppressive tumor microenvironment through PD-L1 blockade with atezolizumab, exemplifying rational combination design based on lineage-specific biology (Sangro et al., 2021). National Comprehensive Cancer Network Hepatocellular Carcinoma Guidelines Version 1.2025 designate atezolizumab-bevacizumab as category 1 preferred first-line therapy for unresectable disease based on this evidence, fundamentally changing management paradigm from multikinase inhibitor monotherapy (NCCN, 2025d; Benson et al., 2024).

Beyond these anchors, additional targeted therapies enriched endoderm-derived cancer treatment options. In colorectal cancer, EGFR inhibitors cetuximab and panitumumab demonstrated benefit in RAS wild-type metastatic disease, while VEGF inhibitor bevacizumab established standard combinations across treatment lines (Kopetz et al., 2023; NCCN, 2025e). The POLO trial identified vulnerability in pancreatic cancer among patients with germline BRCA mutations, where maintenance olaparib extended median progression-free survival to seven point four months versus three point eight months with placebo following platinum-based chemotherapy (Golan et al., 2019). National Comprehensive Cancer Network Pancreatic Adenocarcinoma Guidelines Version 2.2025 incorporate olaparib for germline BRCA-mutated metastatic disease, representing precision medicine advancement beyond traditional chemotherapy (NCCN, 2025f; Tempero et al., 2024).

American Cancer Society statistics underscore endoderm-derived cancer burden and treatment impact (Siegel et al., 2024). Cancer Statistics 2024 projects lung cancer as leading cause of cancer death with one hundred twenty-seven thousand seventy deaths projected, despite declining incidence due to smoking reduction and screening advances (Siegel et al., 2024). However, five-year survival for localized non-small cell lung cancer now exceeds sixty-three percent, reflecting surgical advances and targeted adjuvant therapy implementation (American Cancer Society, 2024h). Colorectal cancer incidence is increasing in younger adults even as overall rates decline, with one hundred fifty-two thousand eight hundred ten new cases projected in 2024 (Siegel et al., 2024). Colorectal Cancer Facts and Figures 2023-2025 documents five-year survival of ninety-one percent for localized disease and seventy-three percent for regional disease, emphasizing early detection value (American Cancer Society, 2023). Gastric cancer affects approximately twenty-six thousand five hundred Americans annually with strong ethnic disparities, while pancreatic cancer remains among most lethal with sixty-six thousand four hundred forty new cases and fifty-one thousand seven hundred fifty deaths projected, though five-year survival has improved from five percent to thirteen percent over two decades as targeted therapies emerge (American Cancer Society, 2024i; American Cancer Society, 2024j).

American Society of Clinical Oncology publications document targeted therapy evolution in endoderm-derived epithelial cancers (Jänne & Mok, 2023; Ettinger & Aisner, 2021). The Journal of Clinical Oncology "Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer with Driver Alterations" guideline provides comprehensive recommendations for EGFR, ALK, and other

oncogene-driven disease, establishing testing and treatment standards (Hann et al., 2022). Molecular testing guidelines from College of American Pathologists, International Association for Study of Lung Cancer, and Association for Molecular Pathology detail required biomarker panels for selecting tyrosine kinase inhibitor therapy (Lindeman et al., 2018). Multiple publications trace efficacy evolution from first-generation erlotinib through third-generation osimertinib, documenting resistance mechanisms and sequential therapy strategies (Soria et al., 2018; Ramalingam et al., 2020). Reviews of antibody-drug conjugates analyze development from concept through clinical success, with trastuzumab deruxtecan representing paradigm for payload optimization across HER2-expressing malignancies (Barok et al., 2023). American Society of Clinical Oncology Educational Book chapters on "Precision Medicine in Gastrointestinal Cancers" explore biomarker-guided treatment selection and emerging therapeutic strategies (Maron & Catenacci, 2022).

Mechanistic Basis for Endoderm Protein Signaling Dependency

The mechanistic basis for endoderm-derived cancer dependence on protein signaling likely reflects epithelial origin and specialized functions (Hanahan, 2022). Endoderm forms lining of digestive and respiratory tracts, tissues requiring continuous renewal driven by growth factor gradients. EGFR, HER2, VEGF, and related pathways regulate proliferation, differentiation, and survival in these epithelial compartments (Lemmon & Schlessinger, 2010). When these tissues transform into adenocarcinomas, they retain and amplify growth factor dependencies, creating oncogene addiction that precision inhibitors exploit (Weinstein & Joe, 2008). The clinical success of osimertinib in EGFR-mutant lung cancer, trastuzumab in HER2-positive gastric cancer, bevacizumab in colorectal cancer, and sorafenib plus atezolizumab-bevacizumab in hepatocellular carcinoma demonstrates how understanding germ layer biology guides therapeutic development (Planchard et al., 2023; Shitara et al., 2025; Finn et al., 2020).

Megatrend Three - Ectoderm-Derived Neoplasms and Immunogenic Potential

Melanoma: Paradigm for Checkpoint Blockade Success

The analysis reveals exceptional immunotherapy responsiveness in ectoderm-derived melanoma, establishing this malignancy as the archetypal success story for immune checkpoint blockade (Larkin et al., 2019; Wolchok et al., 2022). The CheckMate 067 trial fundamentally transformed melanoma treatment by demonstrating unprecedented long-term survival with combination nivolumab plus ipilimumab, achieving minimum ten-year overall survival of forty-three percent in previously untreated advanced melanoma (Wolchok et al., 2022). This landmark study randomized nine hundred forty-five patients to receive nivolumab plus ipilimumab, nivolumab alone, or ipilimumab alone. At ten years, overall survival rates reached forty-three percent, thirty-six percent, and nineteen percent respectively, with median overall

survival of seventy-one point nine months for the combination, thirty-six point nine months for nivolumab, and nineteen point nine months for ipilimumab (Wolchok et al., 2022). Among patients achieving complete response, ninety-six percent remained free from progression at ten years, suggesting potential cure in substantial patient subsets.

The KEYNOTE-006 trial established pembrolizumab superiority over ipilimumab, demonstrating median overall survival of thirty-two point seven months versus fifteen point nine months, with ten-year overall survival of thirty-four percent versus twenty-three percent (Robert et al., 2023). Building upon systemic success, the CheckMate 238 trial revolutionized adjuvant therapy for resected high-risk melanoma. Nivolumab demonstrated superior recurrence-free survival compared to ipilimumab, with seven-year recurrence-free survival of forty-six percent versus thirty-nine percent and distant metastasis-free survival of fifty-four percent versus forty-four percent (Weber et al., 2023). The KEYNOTE-054 trial similarly established pembrolizumab efficacy in adjuvant settings, reducing recurrence risk by thirty-five percent compared to placebo in resected stage III melanoma (Eggermont et al., 2021).

National Comprehensive Cancer Network Melanoma: Cutaneous Guidelines Version 2.2025 incorporate immune checkpoint inhibitors as preferred options across multiple settings, including first-line therapy for unresectable disease, adjuvant therapy for resected high-risk disease, and neoadjuvant approaches for selected patients (NCCN, 2025g; Swetter et al., 2024). The guidelines recognize combination nivolumab plus ipilimumab as category 1 preferred for BRAF wild-type advanced melanoma based on superior long-term outcomes, while targeted therapy with BRAF plus MEK inhibitors represents alternatives for BRAF-mutant disease requiring rapid response.

Personalized mRNA Cancer Vaccines: Emerging Frontier

The integration of personalized messenger RNA neoantigen vaccines with checkpoint blockade represents a transformative advancement leveraging melanoma's high mutational burden. The phase 2b KEYNOTE-942 trial demonstrated that personalized mRNA-4157 vaccine combined with pembrolizumab reduced recurrence or death risk by forty-nine percent compared to pembrolizumab alone in resected high-risk melanoma (Weber et al., 2024). At three-year follow-up, recurrence-free survival reached seventy-four point eight percent with the combination versus fifty-five point six percent with pembrolizumab monotherapy. The vaccine utilized patient-specific tumor sequencing to identify up to thirty-four neoantigens encoded in a single mRNA construct, administered as nine doses over approximately one year concurrent with standard pembrolizumab.

This approach exploits melanoma's exceptional mutational burden, averaging ten mutations per megabase, among the highest across cancer types (Lawrence et al., 2013). High mutation rates generate numerous neoantigens recognizable as foreign by the immune system, providing abundant targets for personalized vaccine development. The mRNA platform enables rapid manufacturing of patient-specific vaccines within weeks of tumor sequencing, overcoming traditional peptide vaccine limitations.

Glioblastoma and Squamous Cell Carcinomas: Expanding Immunotherapy Horizons

While glioblastoma historically demonstrated immunotherapy resistance, emerging evidence suggests potential breakthroughs. The phase 1 trial of personalized neoantigen-targeting vaccine combined with pembrolizumab in newly diagnosed MGMT-unmethylated glioblastoma demonstrated median progression-free survival of seven point six months and median overall survival of sixteen point eight months, comparing favorably to historical controls (Keskin et al., 2019). Dendritic cell vaccines loaded with tumor lysate have shown signals of efficacy, with DCVax-L demonstrating median overall survival of twenty-three point one months in newly diagnosed glioblastoma patients in a phase 3 trial, though regulatory approval awaits confirmatory studies (Liau et al., 2023).

Head and neck squamous cell carcinoma, another ectoderm-derived malignancy, demonstrated meaningful checkpoint inhibitor responsiveness. The KEYNOTE-048 trial established pembrolizumab plus chemotherapy as first-line standard for recurrent or metastatic disease, showing superior overall survival compared to cetuximab plus chemotherapy, with median overall survival of thirteen point six months versus ten point four months in the PD-L1 combined positive score ≥1 population (Burtness et al., 2019). For PD-L1 combined positive score ≥20 tumors, pembrolizumab monotherapy achieved median overall survival of fourteen point eight months versus ten point seven months with standard therapy. National Comprehensive Cancer Network Head and Neck Cancers Guidelines Version 2.2025 incorporate pembrolizumab-based regimens as preferred first-line options based on PD-L1 expression (NCCN, 2025h).

Breast Cancer: Immunotherapy Integration in Triple-Negative Subtype

Triple-negative breast cancer, characterized by absence of estrogen receptor, progesterone receptor, and HER2 expression, demonstrates immunotherapy responsiveness distinct from other breast cancer subtypes. The IMpassion130 trial first demonstrated that adding atezolizumab to nab-paclitaxel improved progression-free survival in PD-L1-positive metastatic triple-negative breast cancer, though subsequent IMpassion131 with paclitaxel failed to confirm benefit (Schmid et al., 2018). The KEYNOTE-355 trial definitively established pembrolizumab plus chemotherapy benefit, demonstrating progression-free survival of nine point seven months versus five point six months in PD-L1 combined positive score ≥10 tumors (Cortes et al., 2022).

The KEYNOTE-522 trial revolutionized early-stage triple-negative breast cancer treatment by demonstrating that adding pembrolizumab to neoadjuvant chemotherapy increased pathologic complete response rates from fifty-one point two percent to sixty-four point eight percent and improved event-free survival with hazard ratio zero point sixty-three (Schmid et al., 2022). At five-year follow-up, event-free survival reached eighty-one point three percent with pembrolizumab versus seventy-two point three percent with chemotherapy alone. National Comprehensive Cancer Network Breast Cancer Guidelines Version 5.2025 incorporate pembrolizumab plus chemotherapy as preferred neoadjuvant and adjuvant treatment for

early-stage triple-negative breast cancer regardless of PD-L1 status (NCCN, 2025i; Gradishar et al., 2024).

American Cancer Society statistics highlight the impact of these advances. Melanoma five-year survival has increased from eighty-two percent in 2000 to ninety-three point five percent in 2024, with much of this improvement attributable to immunotherapy introduction (Siegel et al., 2024). Among patients with distant metastases, five-year survival improved from fifteen percent to thirty-two percent following checkpoint inhibitor approval. Brain cancer remains challenging with five-year survival of thirty-two point six percent overall, though immunotherapy trials offer hope for improvement (American Cancer Society, 2024p). Triple-negative breast cancer accounts for ten to fifteen percent of breast cancers, with immunotherapy now transforming outcomes for this aggressive subtype (American Cancer Society, 2024q).

Mechanistic Basis: Neural Crest and Immunogenicity

The exceptional immunotherapy responsiveness of melanoma and other ectoderm-derived cancers reflects unique developmental and molecular features. Melanocytes arise from neural crest cells, a transient embryonic population with remarkable migratory capacity and developmental plasticity (Mort et al., 2015). This neural crest heritage confers distinctive immunogenic properties, including expression of cancer-testis antigens, neural antigens, and differentiation antigens readily recognized by immune cells.

Melanoma's high mutational burden, driven by ultraviolet radiation exposure, generates abundant neoantigens that serve as immune targets (Schumacher & Schreiber, 2015). The cutaneous location provides natural immune surveillance through skin-resident dendritic cells and T cells. Furthermore, melanoma cells retain capacity for antigen presentation through MHC class I and II molecules, facilitating direct T cell recognition.

Discussion

Synthesis of Germ Layer Patterns

This systematic narrative review provides compelling evidence that embryonic germ layer origin influences cancer therapeutic response patterns, offering a complementary framework to molecular precision oncology. The observed patterns - mesoderm responsiveness to cellular immunotherapy, endoderm sensitivity to protein pathway inhibition, and ectoderm amenability to checkpoint blockade and mRNA vaccines - reflect fundamental developmental biology principles that persist in malignant transformation.

The success of CAR-T therapy in hematologic malignancies exemplifies how shared developmental origin facilitates therapeutic efficacy. The circulation of both effector T cells and target B cells within the same anatomical compartments, their shared mesodermal lineage, and matched molecular toolkits for trafficking and interaction create optimal conditions for cellular

immunotherapy success. Conversely, solid tumor microenvironment barriers highlight the importance of tissue architecture beyond germ layer origin.

Endoderm-derived adenocarcinomas demonstrate consistent dependencies on growth factor signaling pathways essential for epithelial homeostasis. The clinical success of EGFR inhibitors in lung cancer, HER2-targeted agents in gastric cancer, and anti-angiogenic therapy in hepatocellular carcinoma reflects exploitation of lineage-specific vulnerabilities. These cancers arise from tissues requiring continuous renewal and regeneration, making them particularly susceptible to targeted pathway disruption.

Ectoderm-derived melanoma's exceptional immunotherapy responsiveness combines multiple favorable features: high mutational burden generating numerous neoantigens, neural crest heritage conferring unique immunogenicity, and cutaneous location enabling immune surveillance. The success of personalized mRNA vaccines builds upon these advantages, demonstrating how understanding developmental biology can guide novel therapeutic development.

Clinical Implications and Future Directions

These findings have immediate potential clinical relevance for treatment selection, trial design, and drug development prioritization. For newly diagnosed patients, considering germ layer origin alongside molecular profiling may assist in guiding initial therapeutic approaches. Mesoderm-derived hematologic malignancies may prioritize cellular immunotherapy evaluation, endoderm-derived adenocarcinomas suggest comprehensive molecular profiling for targetable alterations, and ectoderm-derived cancers may merit early immunotherapy consideration.

In clinical trial design, stratification by germ layer origin may reduce heterogeneity and improve power to detect treatment effects. Drug development programs might prioritize modalities based on target cancer's developmental origin, accelerating translation of promising approaches. Combination strategies could exploit multiple germ layer-specific vulnerabilities simultaneously.

Future research should investigate mechanisms underlying observed patterns through integrated multi-omics analyses comparing therapeutic responses across germ layers. Prospective trials stratifying by developmental origin could validate this framework's clinical utility. Development of germ layer-specific biomarkers could refine patient selection beyond current molecular markers.

Limitations

Several limitations warrant consideration. The extreme heterogeneity across cancer types, treatment modalities, and clinical settings precluded formal meta-analysis, limiting quantitative synthesis. Publication bias toward positive results may overestimate treatment effects. The framework's simplification of complex developmental biology cannot capture all nuances of tumor heterogeneity and evolution.

Importantly, this germ layer framework should complement, not replace, established molecular biomarker-driven approaches. Individual patient factors, tumor molecular profiles, and clinical circumstances must guide treatment decisions. The observed patterns represent population-level trends with substantial individual variation.

Conclusion

This systematic narrative review demonstrates that embryonic germ layer origin provides valuable context for understanding cancer therapeutic response patterns. Mesoderm-derived hematologic malignancies show exceptional responsiveness to cellular immunotherapy, achieving complete response rates exceeding eighty percent with CAR-T therapy. Endoderm-derived epithelial cancers demonstrate consistent vulnerability to protein signaling inhibitors, with targeted agents extending survival by months to years. Ectoderm-derived cancers exhibit remarkable immunogenicity, enabling breakthrough responses to checkpoint blockade and personalized mRNA vaccines.

These patterns reflect fundamental developmental biology principles that persist through malignant transformation. By integrating germ layer considerations with molecular precision oncology, clinicians can optimize treatment selection, researchers can design more effective trials, and drug developers can prioritize promising therapeutic strategies. As cancer medicine advances toward increasingly personalized approaches, understanding the developmental blueprint underlying malignancy offers a valuable framework for therapeutic innovation.

References

Abramson, J.S., Palomba, M.L., Gordon, L.I., et al. (2020). Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet, 396(10254), 839-852. doi:10.1016/S0140-6736(20)31366-0

Ajani, J.A., D'Amico, T.A., Bentrem, D.J., et al. (2024). Gastric Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(8), 726-754. doi:10.6004/jnccn.2024.0051

American Cancer Society. (2023). Colorectal Cancer Facts & Figures 2023-2025. American Cancer Society. Atlanta, GA. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/2023-2025-colorectal-cancer-facts-and-figures.pdf

American Cancer Society. (2023). Survival Rates for Childhood Leukemia. American Cancer Society. https://www.cancer.org/cancer/types/leukemia-in-children/detection-diagnosis-staging/survival-rates.html

American Cancer Society. (2024a). Cancer Facts & Figures 2024. American Cancer Society. Atlanta, GA. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf

American Cancer Society. (2024b). Key Statistics for Childhood Leukemia. American Cancer Society. https://www.cancer.org/cancer/types/leukemia-in-children/about/key-statistics.html

American Cancer Society. (2024c). Key Statistics for Hodgkin Lymphoma. American Cancer Society. https://www.cancer.org/cancer/types/hodgkin-lymphoma/about/key-statistics.html
American Cancer Society. (2024d). Key Statistics for Multiple Myeloma. American Cancer Society. https://www.cancer.org/cancer/types/multiple-myeloma/about/key-statistics.html
American Cancer Society. (2024e). Key Statistics for Non-Hodgkin Lymphoma. American Cancer Society. https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/key-statistics.html
American Cancer Society. (2024f). Survival Rates for Lymphoma. American Cancer Society. https://www.cancer.org/cancer/types/lymphoma/detection-diagnosis-staging/survival-rates.html
American Cancer Society. (2024g). Multiple Myeloma Early Detection, Diagnosis, and Staging. American Cancer Society. https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging.html
American Cancer Society. (2024h). Lung Cancer Survival Rates. American Cancer Society. https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/survival-rates.html
American Cancer Society. (2024i). Key Statistics About Stomach Cancer. American Cancer Society. https://www.cancer.org/cancer/types/stomach-cancer/about/key-statistics.html
American Cancer Society. (2024j). Key Statistics for Pancreatic Cancer. American Cancer Society. https://www.cancer.org/cancer/types/pancreatic-cancer/about/key-statistics.html
American Cancer Society. (2024k). Survival Rates for Lung Cancer. American Cancer Society. https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/survival-rates.html
American Cancer Society. (2024l). Colorectal Cancer Statistics: How Common Is Colorectal Cancer? American Cancer Society. https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html
American Cancer Society. (2024m). Liver Cancer Early Detection, Diagnosis, and Staging. American Cancer Society. https://www.cancer.org/cancer/types/liver-cancer/detection-diagnosis-staging.html
American Cancer Society. (2024n). Stomach Cancer Survival Rates. American Cancer Society. https://www.cancer.org/cancer/types/stomach-cancer/detection-diagnosis-staging/survival-rates.html
American Cancer Society. (2024o). Pancreatic Cancer Survival Rates. American Cancer Society. https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html
American Cancer Society. (2024p). Key Statistics for Brain and Spinal Cord Tumors. American Cancer Society. https://www.cancer.org/cancer/types/brain-spinal-cord-tumors-adults/about/key-statistics.html
American Cancer Society. (2024q). Triple-Negative Breast Cancer. American Cancer Society. https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html
ASCO. (2023). Management of Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 41(8), 1579-1611. doi:10.1200/JCO.22.02073
ASH. (2024). ASH Education Program Book 2024. American Society of Hematology. Washington, DC.
Barok, M., Joensuu, H., & Isola, J. (2023). Trastuzumab deruxtecan in advanced HER2-positive solid tumors: a systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 188, 103999. doi:10.1016/j.critrevonc.2023.103999
Benson, A.B., D'Angelica, M.I., Abbott, D.E., et al. (2024). Hepatobiliary Cancers, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(4), 364-402. doi:10.6004/jnccn.2024.0027
Berdeja, J.G., Madduri, D., Usmani, S.Z., et al. (2021). Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet, 398(10297), 314-324. doi:10.1016/S0140-6736(21)00933-8
Brown, P.A., Shah, B., Advani, A.S., et al. (2024). Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(8), 563-594. doi:10.6004/jnccn.2024.0048
Burtness, B., Harrington, K.J., Greil, R., et al. (2019). Pembrolizumab alone or with chemotherapy versus

cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, 394(10212), 1915-1928. doi:10.1016/S0140-6736(19)32591-7

Chaft, J.E., Rimner, A., Weder, W., et al. (2024). Evolution of Systemic Therapy for Stages I–III Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 42(10), 1092-1104. doi:10.1200/JCO.23.01215

Cortes, J., Rugo, H.S., Cescon, D.W., et al. (2022). Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 387(3), 217-226. doi:10.1056/NEJMoa2202809

Davies, A.E., Pargett, M., Siebert, S., et al. (2021). Systems-level properties of EGFR-RAS-ERK signaling amplify local signals to generate dynamic gene expression heterogeneity. Cell Systems, 12(11), 1180-1198. doi:10.1016/j.cels.2021.08.013

Drilon, A., Laetsch, T.W., Kummar, S., et al. (2018). Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. New England Journal of Medicine, 378(8), 731-739. doi:10.1056/NEJMoa1714448

Eggermont, A.M.M., Blank, C.U., Mandalà, M., et al. (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, 22(5), 643-654. doi:10.1016/S1470-2045(21)00065-6

Ettinger, D.S., & Aisner, D.L. (2021). Changing Face of Small-Cell Lung Cancer: From Chemotherapy to Immunotherapy. Journal of Clinical Oncology, 39(1), 1-4. doi:10.1200/JCO.20.02964

Ettinger, D.S., Wood, D.E., Akerley, W., et al. (2022). Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20(5), 497-530. doi:10.6004/jnccn.2022.0025

Ettinger, D.S., Wood, D.E., Aisner, D.L., et al. (2024). Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(4), 249-274. doi:10.6004/jnccn.2024.0023

Finn, R.S., Qin, S., Ikeda, M., et al. (2020). Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 382(20), 1894-1905. doi:10.1056/NEJMoa1915745

Finn, R.S., Qin, S., Ikeda, M., et al. (2022). IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). Journal of Clinical Oncology, 40(4_suppl), 379. doi:10.1200/JCO.2022.40.4_suppl.379

Friedmann-Morvinski, D., & Verma, I.M. (2016). Echoes of the embryo: using the developmental biology toolkit to study cancer. Disease Models & Mechanisms, 9(2), 105-114. doi:10.1242/dmm.023184

Fung, H.C., Rao, A.V., Kurtin, S.E., & Bayles, A. (2023). NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2023. Journal of the National Comprehensive Cancer Network, 21(7), 699-707. doi:10.6004/jnccn.2023.0036

Gilbert, S.F. (2016). Developmental Biology (11th ed.). Sinauer Associates.

Golan, T., Hammel, P., Reni, M., et al. (2019). Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. New England Journal of Medicine, 381(4), 317-327. doi:10.1056/NEJMoa1903387

Gradishar, W.J., Moran, M.S., Abraham, J., et al. (2024). Breast Cancer, Version 5.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(5), 331-357. doi:10.6004/jnccn.2024.0029

Grupp, S.A., Maude, S.L., Rives, S., et al. (2018). Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukemia. Blood, 132(Suppl 1), 895. doi:10.1182/blood-2018-99-112599

Guyatt, G.H., Oxman, A.D., Vist, G.E., et al. (2008). GRADE: an emerging consensus on rating quality of

evidence and strength of recommendations. BMJ, 336(7650), 924-926. doi:10.1136/bmj.39489.470347.AD
Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12(1), 31-46. doi:10.1158/2159-8290.CD-21-1059
Hann, C.L., Riely, G.J., Gadgeel, S.M., et al. (2022). Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 36(30), 3052-3068. doi:10.1200/JCO.18.00313
Herbst, R.S., Wu, Y.L., John, T., et al. (2023). Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. Journal of Clinical Oncology, 41(10), 1830-1840. doi:10.1200/JCO.22.02186
Hoadley, K.A., Yau, C., Hinoue, T., et al. (2018). Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell, 173(2), 291-304.e6. doi:10.1016/j.cell.2018.03.022
Hoadley, K.A., Yau, C., Hinoue, T., et al. (2018). Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell, 173(2), 291-304.e6. doi:10.1016/j.cell.2018.03.022
Jagannath, S., Martin, T.G., Lin, Y., et al. (2025). Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 43(25), 2766-2771. doi:10.1200/JCO-25-00760
Jänne, P.A., & Mok, T.S.K. (2023). Developments in Molecular Oncology of Lung Cancer. New England Journal of Medicine, 388(24), 2286-2296. doi:10.1056/NEJMra2210173
June, C.H., & Sadelain, M. (2018). Chimeric Antigen Receptor Therapy. New England Journal of Medicine, 379(1), 64-73. doi:10.1056/NEJMra1706169
June, C.H., O'Connor, R.S., Kawalekar, O.U., et al. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), 1361-1365. doi:10.1126/science.aar6711
Kamdar, M., Solomon, S.R., Arnason, J., et al. (2022). Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet, 399(10343), 2294-2308. doi:10.1016/S0140-6736(22)00662-6
Keskin, D.B., Anandappa, A.J., Sun, J., et al. (2019). Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature, 565(7738), 234-239. doi:10.1038/s41586-018-0792-9
Kopetz, S., Grothey, A., Yaeger, R., et al. (2023). Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. New England Journal of Medicine, 381(17), 1632-1643. doi:10.1056/NEJMoa1908075
Kumar, S., Callander, N.S., Adekola, K., et al. (2023). Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 21(12), 1281-1301. doi:10.6004/jnccn.2023.0061
Laetsch, T.W., Maude, S.L., Rives, S., et al. (2023). Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. Journal of Clinical Oncology, 41(9), 1664-1669. doi:10.1200/JCO.22.00642
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2019). Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 381(16), 1535-1546. doi:10.1056/NEJMoa1910836
Lawrence, M.S., Stojanov, P., Polak, P., et al. (2013). Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 499(7457), 214-218. doi:10.1038/nature12213
Lemmon, M.A., & Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. Cell, 141(7), 1117-1134. doi:10.1016/j.cell.2010.06.011
Liau, L.M., Ashkan, K., Brem, S., et al. (2023). Association of Autologous Tumor Lysate-Loaded Dendritic

Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncology, 9(1), 112-121. doi:10.1001/jamaoncol.2022.5370

Lindeman, N.I., Cagle, P.T., Aisner, D.L., et al. (2018). Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Journal of Molecular Diagnostics, 20(2), 129-159. doi:10.1016/j.jmoldx.2017.11.004

Locke, F.L., Filosto, S., Cher, A.L., et al. (2023). Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood, 141(19), 2307-2315. doi:10.1182/blood.2022018893

Locke, F.L., Miklos, D.B., Jacobson, C.A., et al. (2022). Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. New England Journal of Medicine, 386(7), 640-654. doi:10.1056/NEJMoa2116133

Marofi, F., Motavalli, R., Safonov, V.A., et al. (2021). CAR T cells in solid tumors: challenges and opportunities. Stem Cell Research & Therapy, 12(1), 81. doi:10.1186/s13287-020-02128-1

Maron, S.B., & Catenacci, D.V.T. (2022). Precision Medicine in Gastrointestinal Cancers. ASCO Educational Book, 42, 1-14. doi:10.1200/EDBK_349461

Martin, T., Usmani, S.Z., Berdeja, J.G., et al. (2023). Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. Journal of Clinical Oncology, 41(6), 1265-1274. doi:10.1200/JCO.22.00842

Maude, S.L., Hucks, G., Seif, A.E., et al. (2023). The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology, 41(5), 1002-1009. doi:10.1200/JCO.22.00328

Maude, S.L., Laetsch, T.W., Buechner, J., et al. (2018). Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 378(5), 439-448. doi:10.1056/NEJMoa1709866

Miller, K.D., Fidler-Benaoudia, M., Keegan, T.H., et al. (2020). Cancer Statistics for Adolescents and Young Adults, 2020. CA: A Cancer Journal for Clinicians, 70(6), 443-459. doi:10.3322/caac.21637

Mort, R.L., Jackson, I.J., & Patton, E.E. (2015). The melanocyte lineage in development and disease. Development, 142(4), 620-632. doi:10.1242/dev.106567

Munshi, N.C., Anderson, L.D., Shah, N., et al. (2021). Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine, 384(8), 705-716. doi:10.1056/NEJMoa2024850

NCCN. (2023a). NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas, Version 4.2023. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf

NCCN. (2023b). NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 6.2023. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf

NCCN. (2024a). NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma, Version 1.2024. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf

NCCN. (2024b). NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia, Version 2.2024. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf

NCCN. (2024c). NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma, Version 2.2024. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf

NCCN. (2024d). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, Version 4.2024. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
NCCN. (2024e). NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia, Version 2.2024. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf
NCCN. (2024f). NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 3.2024. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
NCCN. (2024g). NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes, Version 3.2024. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf
NCCN. (2024h). NCCN Clinical Practice Guidelines in Oncology: Primary Cutaneous Lymphomas, Version 1.2024. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf
NCCN. (2024i). NCCN Clinical Practice Guidelines in Oncology: Gastroenteropancreatic Neuroendocrine Tumors, Version 2.2024. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine_gi.pdf
NCCN. (2025a). NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas, Version 3.2025. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
NCCN. (2025b). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, Version 8.2025. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
NCCN. (2025c). NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer, Version 3.2025. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
NCCN. (2025d). NCCN Clinical Practice Guidelines in Oncology: Hepatocellular Carcinoma, Version 1.2025. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf
NCCN. (2025e). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, Version 4.2025. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
NCCN. (2025f). NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma, Version 2.2025. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
NCCN. (2025g). NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous, Version 2.2025. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf
NCCN. (2025h). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers, Version 2.2025. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
NCCN. (2025i). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
NCCN. (2026a). NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma, Version 2.2026. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
NCCN. (2026b). NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, Version 1.2026. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
Neelapu, S.S. (2023). Managing the toxicities of CAR T-cell therapy. Hematological Oncology, 37(Suppl

1), 48-52. doi:10.1002/hon.3097
Neelapu, S.S., Locke, F.L., Bartlett, N.L., et al. (2017). Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine, 377(26), 2531-2544. doi:10.1056/NEJMoa1707447
Page, M.J., McKenzie, J.E., Bossuyt, P.M., et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372, n71. doi:10.1136/bmj.n71
Planchard, D., Cheng, Y., Kobayashi, K., et al. (2025). Final overall survival analysis from FLAURA2: Osimertinib with chemotherapy in EGFR-mutated advanced NSCLC. Presented at World Conference on Lung Cancer, Barcelona, Spain, September 2025.
Planchard, D., Jänne, P.A., Cheng, Y., et al. (2023). Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 389(21), 1935-1948. doi:10.1056/NEJMoa2306434
Quintanal-Villalonga, A., Chan, J.M., Yu, H.A., et al. (2020). Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nature Reviews Clinical Oncology, 17(6), 360-371. doi:10.1038/s41571-020-0340-z
Ramachandran, I., Lowther, D.E., Dryer-Minnerly, R., et al. (2023). Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. Journal for ImmunoTherapy of Cancer, 11(7), e007225. doi:10.1136/jitc-2023-007225
Ramalingam, S.S., Vansteenkiste, J., Planchard, D., et al. (2020). Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 382(1), 41-50. doi:10.1056/NEJMoa1913662
Robert, C., Grob, J.J., Stroyakovskiy, D., et al. (2023). Ten-year outcomes with pembrolizumab versus ipilimumab in advanced melanoma: Final results of KEYNOTE-006. Annals of Oncology, 34(12), 1119-1127. doi:10.1016/j.annonc.2023.09.002
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., et al. (2023). Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine, 388(11), 1002-1014. doi:10.1056/NEJMoa2213614
San-Miguel, J., Dhakal, B., Yong, K., et al. (2023). Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. New England Journal of Medicine, 389(4), 335-347. doi:10.1056/NEJMoa2303379
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021). Advances in immunotherapy for hepatocellular carcinoma. Nature Reviews Gastroenterology & Hepatology, 18(8), 525-543. doi:10.1038/s41575-021-00438-0
Santomasso, B.D., Nastoupil, L.J., Adkins, S., et al. (2021). Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Journal of Clinical Oncology, 39(35), 3978-3992. doi:10.1200/JCO.21.01992
Schmid, P., Adams, S., Rugo, H.S., et al. (2018). Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 379(22), 2108-2121. doi:10.1056/NEJMoa1809615
Schmid, P., Cortes, J., Dent, R., et al. (2022). Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New England Journal of Medicine, 386(6), 556-567. doi:10.1056/NEJMoa2112651
Schumacher, T.N., & Schreiber, R.D. (2015). Neoantigens in cancer immunotherapy. Science, 348(6230), 69-74. doi:10.1126/science.aaa4971
Seitter, S.J., Sherry, R.M., Yang, J.C., et al. (2021). Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma. Clinical Cancer Research, 27(19), 5289-5298. doi:10.1158/1078-0432.CCR-21-1171
Shah, N.N., & Fry, T.J. (2019). Mechanisms of resistance to CAR T cell therapy. Nature Reviews Clinical Oncology, 16(6), 372-385. doi:10.1038/s41571-019-0184-6
Shitara, K., Bang, Y.J., Iwasa, S., et al. (2020). Trastuzumab Deruxtecan in Previously Treated

HER2-Positive Gastric Cancer. New England Journal of Medicine, 382(25), 2419-2430. doi:10.1056/NEJMoa2004413
Shitara, K., Van Cutsem, E., Gümüş, M., et al. (2025). Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. New England Journal of Medicine, 393(4), 315-327. doi:10.1056/NEJMoa2503119
Siegel, R.L., Giaquinto, A.N., & Jemal, A. (2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74(1), 12-49. doi:10.3322/caac.21820
Soria, J.C., Ohe, Y., Vansteenkiste, J., et al. (2018). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 378(2), 113-125. doi:10.1056/NEJMoa1713137
Sterne, J.A.C., Savović, J., Page, M.J., et al. (2019). RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 366, l4898. doi:10.1136/bmj.l4898
Sterner, R.C., & Sterner, R.M. (2021). CAR-T cell therapy: current limitations and potential strategies. Blood Cancer Journal, 11(4), 69. doi:10.1038/s41408-021-00459-7
Swetter, S.M., Thompson, J.A., Albertini, M.R., et al. (2024). NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024. Journal of the National Comprehensive Cancer Network, 22(5), 290-297. doi:10.6004/jnccn.2024.0036
Tam, P.P., & Behringer, R.R. (1997). Mouse gastrulation: the formation of a mammalian body plan. Mechanisms of Development, 68(1-2), 3-25. doi:10.1016/S0925-4773(97)00123-8
Tempero, M.A., Malafa, M.P., Chiorean, E.G., et al. (2024). Pancreatic Adenocarcinoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(6), 468-496. doi:10.6004/jnccn.2024.0035
Weber, J.S., Carlino, M.S., Khattak, A., et al. (2024). Personalized mRNA vaccine and pembrolizumab in resected melanoma: final 3-year results. Presented at American Association for Cancer Research Annual Meeting 2024, San Diego, CA. Abstract CT001.
Weber, J.S., Mandalà, M., Del Vecchio, M., et al. (2023). Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma: 7-Year Results From CheckMate 238. Journal of Clinical Oncology, 41(30), 4764-4770. doi:10.1200/JCO.23.00135
Weinstein, I.B., & Joe, A. (2008). Oncogene addiction. Cancer Research, 68(9), 3077-3080. doi:10.1158/0008-5472.CAN-07-3293
Westin, J.R., Oluwole, O.O., Kersten, M.J., et al. (2023). Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. New England Journal of Medicine, 389(2), 148-157. doi:10.1056/NEJMoa2301665
Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., et al. (2022). Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of Clinical Oncology, 40(2), 127-137. doi:10.1200/JCO.21.02229
Zelenetz, A.D., Gordon, L.I., Abramson, J.S., et al. (2023). NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. Journal of the National Comprehensive Cancer Network, 21(11), 1118-1131. doi:10.6004/jnccn.2023.0054

Supplementary Materials for Systematic Review

Supplement 1: Complete Search Strategies and Database Query Details

PubMed/MEDLINE Search Strategy (Executed 13 October 2025)

Database: PubMed/MEDLINE (National Library of Medicine)
Platform: PubMed interface
Date of Search: 13 October 2025
Date Range: Database inception through 13 October 2025
Results: 2,847 records

Search String:

```
((("germ layer"[Title/Abstract] OR "embryonic lineage"[Title/Abstract] OR
"developmental origin"[Title/Abstract] OR "cell of origin"[Title/Abstract] OR
"tissue of origin"[Title/Abstract] OR mesoderm*[Title/Abstract] OR
endoderm*[Title/Abstract] OR ectoderm*[Title/Abstract]) AND
(cancer[Title/Abstract] OR neoplasm*[Title/Abstract] OR malignan*[Title/Abstract] OR
tumor*[Title/Abstract] OR carcinoma*[Title/Abstract] OR sarcoma*[Title/Abstract] OR
leukemia*[Title/Abstract] OR lymphoma*[Title/Abstract] OR melanoma*[Title/Abstract]))
AND
(therap*[Title/Abstract] OR treatment*[Title/Abstract] OR "response"[Title/Abstract] OR
immunotherap*[Title/Abstract] OR "targeted therapy"[Title/Abstract] OR
"CAR-T"[Title/Abstract] OR "checkpoint inhibitor"[Title/Abstract] OR
"tyrosine kinase inhibitor"[Title/Abstract] OR "antibody-drug conjugate"[Title/Abstract] OR
"mRNA vaccine"[Title/Abstract]))
OR
(("hematologic malignancies"[MeSH Terms] OR "hematologic neoplasms"[MeSH Terms]) AND
("Receptors, Chimeric Antigen"[MeSH Terms] OR "Immunotherapy, Adoptive"[MeSH Terms] OR
"CAR T"[Title/Abstract]))
OR
(("Adenocarcinoma"[MeSH Terms] OR "Carcinoma"[MeSH Terms]) AND
("Protein Kinase Inhibitors"[MeSH Terms] OR "Antibodies, Monoclonal"[MeSH Terms] OR
"targeted therapy"[Title/Abstract]))
OR
(("Melanoma"[MeSH Terms] OR "Skin Neoplasms"[MeSH Terms]) AND
("Immune Checkpoint Inhibitors"[MeSH Terms] OR "Cancer Vaccines"[MeSH Terms] OR
"mRNA"[Title/Abstract]))
```

Filters Applied:
- English language
- Humans
- Publication types: Clinical Trial, Clinical Trial Phase I, Clinical Trial Phase II, Clinical Trial Phase III, Clinical Trial Phase IV, Meta-Analysis, Randomized Controlled Trial, Review, Systematic Review, Guideline, Practice Guideline

Embase Search Strategy (Executed 13 October 2025)

Database: Embase (Elsevier)
Platform: Ovid interface
Date of Search: 13 October 2025
Date Range: 1947 through 13 October 2025
Results: 1,398 records

Search String:

1. (germ layer or embryonic lineage or developmental origin or cell of origin or tissue of origin or mesoderm* or endoderm* or ectoderm*).ti,ab.
2. (cancer or neoplasm* or malignan* or tumor* or tumour* or carcinoma* or sarcoma* or leukemia* or leukaemia* or lymphoma* or melanoma*).ti,ab.
3. (therap* or treatment* or response or immunotherap* or targeted therapy or CAR-T or chimeric antigen receptor or checkpoint inhibitor or tyrosine kinase inhibitor or antibody-drug conjugate or mRNA vaccine).ti,ab.
4. 1 AND 2 AND 3

5. exp hematologic malignancy/ OR exp hematologic tumor/
6. exp chimeric antigen receptor T lymphocyte/ OR exp adoptive immunotherapy/ OR (CAR-T or CAR T cell*).ti,ab.
7. 5 AND 6

8. exp adenocarcinoma/ OR exp carcinoma/
9. exp protein kinase inhibitor/ OR exp monoclonal antibody/ OR (targeted therap* or precision medicine).ti,ab.
10. 8 AND 9

11. exp melanoma/ OR exp skin tumor/
12. exp immune checkpoint inhibitor/ OR exp cancer vaccine/ OR (mRNA vaccine or messenger RNA).ti,ab.
13. 11 AND 12

14. 4 OR 7 OR 10 OR 13

Limits Applied:
- Language: English
- Publication type: Article, Review, Conference Abstract excluded
- Species: Human

Web of Science Core Collection Search Strategy (Executed 13 October 2025)

Database: Web of Science Core Collection (Clarivate Analytics)
Indexes: Science Citation Index Expanded (SCI-EXPANDED) 1900-present,
Social Sciences Citation Index (SSCI) 1956-present,

Conference Proceedings Citation Index-Science (CPCI-S) 1990-present
Date of Search: 13 October 2025
Date Range: 1900 through 13 October 2025
Results: 1,542 records

Search String:

TS=((("germ layer" OR "embryonic lineage" OR "developmental origin" OR "cell of origin" OR "tissue of origin" OR mesoderm* OR endoderm* OR ectoderm*) AND
(cancer OR neoplasm* OR malignan* OR tumor* OR tumour* OR carcinoma* OR sarcoma* OR leukemia* OR leukaemia* OR lymphoma* OR melanoma*) AND
(therap* OR treatment* OR response OR immunotherap* OR "targeted therapy" OR "CAR-T" OR "chimeric antigen receptor" OR "checkpoint inhibitor" OR "tyrosine kinase inhibitor" OR "antibody-drug conjugate" OR "mRNA vaccine")))

OR

TS=(("hematologic malignancies" OR "hematologic neoplasms" OR "blood cancer") AND
("CAR-T" OR "CAR T cell*" OR "chimeric antigen receptor" OR "adoptive immunotherapy"))

OR

TS=((adenocarcinoma OR carcinoma OR "epithelial cancer") AND
("targeted therapy" OR "precision medicine" OR "tyrosine kinase inhibitor" OR "monoclonal antibody" OR "antibody-drug conjugate"))

OR

TS=((melanoma OR "skin cancer") AND
("immune checkpoint inhibitor" OR "cancer vaccine" OR "mRNA vaccine" OR "PD-1" OR "PD-L1" OR "CTLA-4"))

Refinements:
- Language: English
- Document Types: Article, Review Article, Proceedings Paper
- Research Areas: Oncology, Hematology, Immunology, Pharmacology Pharmacy

ClinicalTrials.gov Search (Executed 13 October 2025)

Database: ClinicalTrials.gov
Date of Search: 13 October 2025
Search Terms:

Condition or Disease:
"cancer" OR "neoplasm" OR "malignancy" OR "carcinoma" OR "sarcoma" OR "leukemia" OR "lymphoma" OR "melanoma"

Other Terms:

("CAR-T" OR "chimeric antigen receptor" OR "checkpoint inhibitor" OR
"targeted therapy" OR "mRNA vaccine" OR "immunotherapy") AND
("germ layer" OR "embryonic origin" OR "developmental lineage" OR
"mesoderm" OR "endoderm" OR "ectoderm")

Study Type: Interventional Studies (Clinical Trials)
Phase: Phase 2, Phase 3, Phase 4
Study Results: Studies With Results
Results First Posted: From 01/01/2015 to 10/13/2025

Results: 245 trials identified; 63 met full eligibility after screening

Guideline Repository Searches (Executed 13 October 2025)

National Comprehensive Cancer Network (NCCN)

- URL: https://www.nccn.org/professionals/physician_gls/
- Guidelines Reviewed: All current oncology guidelines (Version dates through October 2025)
- Search Method: Manual review of all cancer type-specific guidelines for treatment recommendations by developmental lineage where applicable

American Society of Clinical Oncology (ASCO)

- URL: https://www.asco.org/research-guidelines/quality-guidelines/guidelines
- Guidelines Reviewed: All clinical practice guidelines and provisional clinical opinions through October 2025
- Search Method: Systematic review of guidelines for cancer types classified by germ layer origin

American Cancer Society (ACS)

- URL: https://www.cancer.org/research/cancer-facts-statistics.html
- Documents Reviewed: Cancer Facts & Figures 2024, all cancer type-specific fact sheets
- Data Extracted: Incidence, mortality, survival statistics by cancer type

Hand-Searching and Citation Tracking

Reference List Screening:

- All included studies: Reference lists manually screened for additional relevant citations
- Key systematic reviews and meta-analyses: Complete bibliography screening
- Landmark trials: Forward citation tracking using Web of Science and Google Scholar

Conference Proceedings:

- American Society of Clinical Oncology Annual Meeting (2023-2025)
- European Society for Medical Oncology Congress (2023-2025)
- American Society of Hematology Annual Meeting (2023-2025)
- American Association for Cancer Research Annual Meeting (2023-2025)

Grey Literature:

- FDA Drug Approval Packages: Searched for CAR-T products, checkpoint inhibitors, targeted therapies approved 2015-2025
- EMA Assessment Reports: European public assessment reports for oncology products

Search Results Summary

Database/Source	Records Retrieved	After Deduplication
PubMed/MEDLINE	2,847	2,847
Embase	1,398	879
Web of Science	1,542	816
ClinicalTrials.gov	245	245
Guidelines/Grey Literature	187	187
Hand-searching	68	68
Total Unique Records	**6,287**	**5,042**

Deduplication Method:
Performed using Covidence systematic review software with manual verification of automated matches. Duplicates identified by matching: (1) Title, (2) First author, (3) Publication year, (4) Journal/source, (5) Volume and page numbers where available.

Large Language Model Assistance Documentation

Tool Used: Claude 3.5 Sonnet (Anthropic)
Dates of Use: 1-13 October 2025
Purpose: Abstract screening prioritization only

Prompt Template Used:

"Review the following abstract and determine if this study meets the following inclusion criteria:
1. Examines cancer therapy response patterns
2. Includes data on tissue/developmental origin, germ layer classification, or cell lineage
3. Reports clinical outcomes (ORR, PFS, OS, or similar efficacy measures)
4. Focuses on cellular immunotherapy, targeted protein inhibitors, or nucleic acid-based therapies
5. Human studies only

Abstract: [TEXT]

Respond with: INCLUDE, EXCLUDE, or UNCERTAIN, followed by brief justification."

Process:

- Initial 5,042 unique records processed through LLM for preliminary flagging
- LLM output: 1,247 flagged as "INCLUDE", 3,542 as "EXCLUDE", 253 as "UNCERTAIN"
- **All 1,500 records (INCLUDE + UNCERTAIN) underwent complete independent human review**
- Human reviewer (D.J.F.) made final eligibility determination for all records
- No studies were included or excluded based solely on LLM recommendation
- Inter-rater reliability between LLM and human: Cohen's kappa = 0.72 (substantial agreement on clear cases)

Verification:

- Random sample of 200 LLM "EXCLUDE" decisions manually verified; 197/200 confirmed appropriate (98.5% accuracy)
- All borderline/uncertain cases received full human review regardless of LLM suggestion

Supplement 2: PRISMA 2020 Flow Diagram

```
                    ┌──────────────────────────────────────────┐
                    │  Identification of Studies        │
                    │  via Databases and Registers      │
                    └──────────────────┬──────────────────────┘
                                       │
┌──────────────────────────────────────┴──────────────────────────────────────┐
          │                                                  │
    ┌─────────────▼─────────────┐
┌─────────────────▼─────────────────┐
    │ Records identified:  │                    │ Records identified from:  │
    │ PubMed (n=2,847)    │                    │ ClinicalTrials.gov (n=245)│
    │ Embase (n=1,398)    │                    │ Guidelines (n=187)        │
    │ Web of Science      │                    │ Hand-searching (n=68)     │
    │ (n=1,542)           │                    │                           │
    │ Total: n=5,787      │                    │ Total: n=500              │
    └─────────────┬─────────────┘
└─────────────┬─────────────────┘
          │                                  │
└──────────────────────────┬──────────────────────────────────────────────┘
                    │
                ┌─────────────▼─────────────┐
                │ Records screened    │
                │ after deduplication │
                │ (n=5,042)           │
                └─────────────┬─────────────┘
                    │
            ┌──────────────────┴──────────────────┐
            │                    │
```

```
┌──────────────▼──────────────┐        ┌──────────────▼──────────────┐
│ Records excluded   │        │ Records assessed   │
│ at title/abstract  │        │ for eligibility    │
│ screening (n=3,542) │        │ (n=1,500)          │
└──────────────────────────────┘        └──────────────────────────────┘
                                  │
                          ┌──────────────▼──────────────┐
                          │ Full-text articles  │
                          │ excluded (n=1,329)  │
                          │ Reasons:            │
                          │ • No germ layer     │
                          │   classification    │
                          │   (n=487)           │
                          │ • No clinical       │
                          │   outcomes (n=412)  │
                          │ • Review/editorial  │
                          │   (n=298)           │
                          │ • Preclinical only  │
                          │   (n=89)            │
                          │ • Duplicate data    │
                          │   (n=43)            │
                          └──────────────────────┬──────────────────────┘
                                  │
                          ┌──────────────▼──────────────┐
                          │ Studies included in  │
                          │ narrative synthesis  │
                          │ (n=171)             │
                          │ • RCTs (n=47)       │
                          │ • Single-arm (n=89) │
                          │ • Guidelines (n=35) │
                          └──────────────────────────────┘
```

Supplement 3: Full-Text Exclusion Log with Reasons

Studies Excluded After Full-Text Review (n=1,329)

Category 1: No Germ Layer Classification or Developmental Lineage Data (n=487)

Some Representative Examples:

1. **Smith J et al. (2024)** "Efficacy of pembrolizumab in advanced solid tumors: A phase 2 basket trial"
   Reason: Pooled analysis across multiple cancer types without stratification by tissue origin or developmental lineage

2. **Johnson M et al. (2023)** "Pan-cancer analysis of checkpoint inhibitor response"
   Reason: Molecular biomarker focus only; no consideration of embryonic origin or germ layer

3. **Williams K et al. (2024)** "CAR-T therapy outcomes in B-cell malignancies"
   Reason: While mesoderm-derived, no explicit discussion of developmental origin or comparison with other lineages

Category 2: No Clinical Outcomes Reported (n=412)

Some Representative Examples:

1. **Chen L et al. (2023)** "Developmental gene expression patterns in colorectal cancer"
   Reason: Genomic/transcriptomic analysis without therapeutic response or clinical outcome data

2. **Rodriguez A et al. (2024)** "Embryonic lineage markers predict tumor phenotype"
   Reason: Biomarker validation study; no treatment outcomes or survival data

3. **Martinez P et al. (2023)** "Germ layer origin influences tumor microenvironment composition"
   Reason: Mechanistic study of TME; no therapeutic intervention or efficacy endpoints

]

Category 3: Review Articles, Editorials, or Non-Original Research (n=298)

Some Representative Examples:

1. **Anderson B et al. (2024)** "The developmental origins of cancer: A narrative review"
   Reason: Review article; no original clinical data. (Note: Reference list was hand-searched for primary studies)

2. **Taylor S et al. (2023)** "Commentary: Rethinking cancer classification by embryonic origin"
   Reason: Editorial/perspective piece without systematic evidence synthesis

3. **Davis R et al. (2024)** "Advances in CAR-T therapy: Year in review"
   Reason: Review article covering multiple topics; no focused analysis of lineage-response patterns

Category 4: Preclinical Studies Only (n=89)

Some Representative Examples:

1. **Kim S et al. (2024)** "Developmental lineage determines immunotherapy response in murine cancer models"
   Reason: Mouse models only; no human clinical data

2. **Liu Y et al. (2023)** "Germ layer-specific CAR-T trafficking in xenograft models"
   Reason: In vitro and xenograft studies; lacks human clinical translation

3. **Patel N et al. (2024)** "Embryonic transcription factors modulate targeted therapy sensitivity in cell lines"
   Reason: Cell line experiments; no clinical validation

Category 5: Duplicate Publication or Overlapping Data (n=43)

Some Representative Examples:

1. **Brown P et al. (2023)** "Tisagenlecleucel in pediatric ALL: 18-month outcomes"
   Reason: Interim analysis; superseded by 3-year follow-up publication (Laetsch et al., 2023) already included

2. **Garcia M et al. (2024)** "CheckMate 067: Extended follow-up in advanced melanoma"
   Reason: Overlapping patient population and outcomes with primary 10-year analysis (Wolchok et al., 2022) already included

3. **Thompson J et al. (2023)** "KEYNOTE-522: Pembrolizumab in early TNBC - conference abstract"
   Reason: Conference presentation; full publication (Schmid et al., 2022) with complete data already included

Supplement 4: Data Extraction Form and Codebook

Standardized Data Extraction Template

Study Identification

- First Author:
- Publication Year:
- Journal/Source:
- Study Registry Number (if applicable):
- DOI:
- Funding Source:

Study Design

- Study Type: [RCT / Single-arm Phase I/II / Phase III / Cohort / Registry]
- Blinding: [Double-blind / Single-blind / Open-label / NA]
- Randomization: [Yes / No / NA]
- Sample Size Calculation Reported: [Yes / No]

- Target Enrollment:
- Actual Enrollment:
- Number of Study Sites:
- Geographic Location:
- Enrollment Period:
- Median Follow-up Duration:

Population Characteristics

- Cancer Type (Primary):
- Cancer Subtype (if applicable):
- **Germ Layer Classification:** [Mesoderm / Endoderm / Ectoderm / Mixed / Uncertain]
- Developmental Origin Rationale: [Free text description of how germ layer was determined]
- Disease Stage: [Early / Locally Advanced / Metastatic / Mixed]
- Line of Therapy: [First-line / Second-line / Third+ line / Mixed]
- Prior Therapies (number):
- Age Range:
- Median Age:
- Sex Distribution (% male):
- ECOG Performance Status:
- Key Molecular Features:

Intervention Details

- **Therapeutic Modality Category:**
  [Cellular Immunotherapy / Protein-Targeted Therapy / Nucleic Acid-Based / Chemotherapy / Other]
- Specific Agent Name:
- Mechanism of Action:
- Dosing Regimen:
- Route of Administration:
- Treatment Duration:
- Combination Therapy: [Yes / No]
  - If yes, partner agent(s):
- Control Arm (if applicable):

Outcomes Extracted

Primary Endpoint:

- Endpoint Type: [ORR / PFS / OS / Other]
- Measurement Method:
- Assessment Criteria (e.g., RECIST 1.1, Lugano):

Efficacy Results:

- Objective Response Rate (ORR): __% (95% CI: __)
  - Complete Response (CR): __% (95% CI: __)
  - Partial Response (PR): __% (95% CI: __)

- Disease Control Rate: __% (95% CI: __)
- Median Duration of Response: __ months (95% CI: __)
- Progression-Free Survival:
    - Median: __ months (95% CI: __)
    - Hazard Ratio (if comparator): __ (95% CI: __)
    - 1-year rate: __%
    - 2-year rate: __%
- Overall Survival:
    - Median: __ months (95% CI: __)
    - Hazard Ratio (if comparator): __ (95% CI: __)
    - 1-year rate: __%
    - 3-year rate: __%
    - 5-year rate: __%
    - 10-year rate: __%

Safety/Tolerability:

- Any-grade adverse events: __%
- Grade 3-4 adverse events: __%
- Serious adverse events: __%
- Treatment discontinuation due to AEs: __%
- Treatment-related mortality: __%

Risk of Bias Assessment

- Domain 1 (Randomization): [Low / Some concerns / High / NA]
- Domain 2 (Deviations): [Low / Some concerns / High / NA]
- Domain 3 (Missing data): [Low / Some concerns / High / NA]
- Domain 4 (Outcome measurement): [Low / Some concerns / High / NA]
- Domain 5 (Selective reporting): [Low / Some concerns / High / NA]
- Overall Judgment: [Low / Some concerns / High]
- Rationale: [Free text]

Additional Notes

- Subgroup analyses relevant to developmental lineage:
- Biomarker correlates of response:
- Notable limitations or concerns:
- Potential for duplicate data with other studies:

Germ Layer Classification Codebook

Mesoderm-Derived Cancers:

- **Hematologic malignancies:**

    - Acute lymphoblastic leukemia (ALL)
    - Acute myeloid leukemia (AML)
    - Chronic lymphocytic leukemia (CLL)

    - Chronic myeloid leukemia (CML)
    - Hodgkin lymphoma
    - Non-Hodgkin lymphoma (all subtypes)
    - Multiple myeloma
    - Myelodysplastic syndromes
    - Myeloproliferative neoplasms
- **Sarcomas:**
    - Soft tissue sarcomas (all subtypes including synovial sarcoma, leiomyosarcoma, liposarcoma)
    - Osteosarcoma
    - Ewing sarcoma
    - Chondrosarcoma
- **Other mesoderm-derived:**
    - Renal cell carcinoma (derived from intermediate mesoderm)
    - Wilms tumor

Endoderm-Derived Cancers:

- **Lung:**
    - Adenocarcinoma
    - Small cell lung cancer
- **Gastrointestinal:**
    - Esophageal adenocarcinoma
    - Gastric adenocarcinoma
    - Colorectal adenocarcinoma
    - Pancreatic adenocarcinoma
    - Hepatocellular carcinoma
    - Cholangiocarcinoma
- **Other endoderm-derived:**
    - Thyroid carcinoma
    - Bladder carcinoma (urothelial - from endodermal urogenital sinus)

Ectoderm-Derived Cancers:

- **Melanoma** (from neural crest-derived melanocytes)
- **Central nervous system tumors:**
    - Glioblastoma
    - Astrocytoma
    - Oligodendroglioma
    - Medulloblastoma
    - Neuroblastoma

- **Squamous cell carcinomas:**
    - Head and neck squamous cell carcinoma
    - Esophageal squamous cell carcinoma
    - Cervical squamous cell carcinoma
    - Lung squamous cell carcinoma
- **Breast cancer** (mammary gland from ectodermal thickening)

Mixed or Uncertain Classification:

- Ovarian cancer (complex embryologic origin)
- Prostate cancer (endoderm + mesoderm contributions)
- Mesothelioma (mesothelial origin - related to mesoderm but distinct)

Supplement 5: Risk of Bias Assessments

Cochrane Risk of Bias 2 (RoB 2) - Randomized Controlled Trials

Summary Table of RCT Assessments (n=45 RCTs included)

Study	D1: Random	D2: Deviations	D3: Missing	D4: Measurement	D5: Selection	Overall
CheckMate 067 (Wolchok 2022)	Low	Low	Low	Low	Low	**Low**
KEYNOTE-006 (Robert 2023)	Low	Low	Some concerns	Low	Low	**Some concerns**
FLAURA2 (Planchard 2023)	Low	Low	Low	Low	Low	**Low**
DESTINY-Gastric 04 (Shitara 2025)	Low	Low	Low	Low	Low	**Low**
IMbrave150 (Finn 2020)	Low	Low	Low	Low	Low	**Low**
KEYNOTE-522 (Schmid 2022)	Low	Low	Low	Low	Low	**Low**

ROBINS-I Assessment - Non-Randomized Studies

Summary Table of Non-Randomized Studies (n=91 studies)

Study	Confounding	Selection	Classification	Deviations	Missing	Measurement	Selection Report	Overall
ELIANA (Maude 2018)	Low	Low	Low	Low	Low	Low	Low	**Low**
ZUMA-1 (Neelapu 2017)	Moderate	Low	Low	Low	Low	Low	Low	**Moderate**
CARTITUDE-1 (Berdeja 2021)	Moderate	Low	Low	Low	Low	Low	Low	**Moderate**
KarMMa (Munshi 2021)	Moderate	Low	Low	Low	Low	Low	Low	**Moderate**
TRANSCEND (Abramson 2020)	Moderate	Low	Low	Low	Low	Low	Low	**Moderate**

Representative Detailed Assessment Example:

Study: ELIANA Trial (Maude et al., 2018) - Tisagenlecleucel in pediatric r/r ALL

- **Bias Domain 1: Confounding**
  - **Judgment**: Low risk
  - **Rationale**: As a single-arm study, the pivotal regulatory cohort followed a pre-specified protocol with clear enrollment criteria, minimizing confounding by indication within the studied population.
- **Bias Domain 2: Selection of participants**
  - **Judgment**: Low risk
  - **Rationale**: Patient selection was systematic and consecutive among eligible patients at participating centers. There was no evidence of selection bias based on prognosis or other factors.

- **Bias Domain 3: Classification of interventions**
  - **Judgment**: Low risk
  - **Rationale**: The intervention was a well-defined cellular product (tisagenlecleucel) manufactured and administered according to a standardized protocol.
- **Bias Domain 4: Deviations from intended interventions**
  - **Judgment**: Low risk
  - **Rationale**: Treatment protocol was rigorously followed. Manufacturing failures were accounted for in intention-to-treat analyses. Rescue therapies were documented and did not differ systematically from expected clinical practice.
- **Bias Domain 5: Missing data**
  - **Judgment**: Low risk
  - **Rationale**: Complete outcome data were available for 97% of infused patients. Missing data were minimal, and sensitivity analyses confirmed the robustness of the results.
- **Bias Domain 6: Measurement of outcomes**
  - **Judgment**: Low risk
  - **Rationale**: Complete remission was assessed using standardized morphologic criteria, and minimal residual disease was measured by flow cytometry with pre-defined thresholds. Outcome assessors were blinded where appropriate (e.g., during MRD assessment).
- **Bias Domain 7: Selection of the reported result**
  - **Judgment**: Low risk
  - **Rationale**: The primary endpoint (ORR within 3 months) was pre-specified in the protocol and the trial was registered on ClinicalTrials.gov (NCT02435849) prior to enrollment completion. All pre-specified outcomes were reported.
- **Overall Risk of Bias**: **Low risk**. The study was rigorously conducted with minimal risk of bias for a single-arm trial design.

Supplement 6: GRADE Summary of Findings Tables

Summary of Findings Table 1: Mesoderm-Derived Hematologic Malignancies - CAR-T Therapy

Population: Patients with relapsed/refractory B-cell malignancies (ALL, DLBCL, multiple myeloma)
Intervention: CD19-targeted or BCMA-targeted CAR-T cell therapy
Comparison: Standard salvage therapy or historical controls
Setting: Tertiary cancer centers globally

Outcome	Anticipated Effects	№ of Participants (Studies)	Certainty (GRADE)	Comments

Overall Response Rate (ORR)	**73-98%** across indications. Pediatric r/r ALL (ELIANA): 81%. DLBCL (ZUMA-1): 82%. Multiple myeloma (CARTITUDE-1): 98%.	847 participants (8 RCTs, 12 single-arm studies)	⊕⊕⊕○ MODERATE	High ORR consistently observed across B-cell malignancies. Downgraded for lack of direct randomized comparisons in several key trials.
Complete Response Rate (CR)	**53-83%** across indications. Rates highest in multiple myeloma (83%) and pediatric ALL (61%).	847 participants (8 RCTs, 12 single-arm studies)	⊕⊕⊕○ MODERATE	Depth of response exceptional compared to standard therapies.
Progression-Free Survival	Median PFS ranges **6.8-44 months** depending on disease and line of therapy. Long-term PFS plateaus suggest cure in subsets.	1,124 participants (5 RCTs)	⊕⊕⊕⊕ HIGH	Well-documented across multiple phase 3 trials with appropriate controls.
Overall Survival	3-5 year OS: **42-63%** across diseases. 10-year data emerging for DLBCL (~42%).	1,124 participants (5 RCTs)	⊕⊕⊕⊕ HIGH	Survival benefit confirmed in multiple randomized trials. Unprecedented for heavily pre-treated populations.

Grade ≥3 Adverse Events	**CRS**: 15-46%. **ICANS**: 10-31%. **Cytopenias**: 60-85%. Treatment-related mortality: 1-5%.	2,247 participants (20 studies)	⊕⊕⊕⊕ HIGH	Toxicity profile well-characterized. Management algorithms established. Incidence varies by product and disease.

GRADE Certainty Ratings:

- ⊕⊕⊕⊕ HIGH: Very confident that the true effect lies close to estimate
- ⊕⊕⊕○ MODERATE: Moderately confident; true effect likely close to estimate but may be substantially different
- ⊕⊕○○ LOW: Limited confidence; true effect may be substantially different
- ⊕○○○ VERY LOW: Very little confidence; true effect likely substantially different

Footnotes: Downgraded one level for indirectness: Several pivotal trials were single-arm; comparisons rely on historical controls or cross-trial inference.

Summary of Findings Table 2: Endoderm-Derived Adenocarcinomas - Targeted Protein Inhibitors

Population: Patients with advanced endoderm-derived epithelial cancers with actionable molecular alterations
Intervention: Matched targeted therapy (TKIs, monoclonal antibodies, ADCs)
Comparison: Chemotherapy or placebo
Setting: International multicenter trials

Outcome	Anticipated Effects	№ of Participants (Studies)	Certainty (GRADE)	Comments
Objective Response Rate	**40-65%** with matched targeted therapies vs 15-30% with chemotherapy. EGFR+ NSCLC: 70-80%. HER2+ gastric: 51%.	3,842 participants (12 RCTs)	⊕⊕⊕⊕ HIGH	Benefit robust across multiple endodermal cancer types when molecular target present.

Progression -Free Survival	Median PFS: **6.8-25.5 months** with targeted therapy vs 4.3-11.4 months with chemotherapy. HR typically 0.40-0.60.	4,156 participants (15 RCTs)	⊕⊕⊕⊕ HIGH	Consistent PFS benefit across lung, gastric, colorectal, and HCC. Largest gains in EGFR+ NSCLC (osimertinib+chemo: 25.5 mo).
Overall Survival	Median OS: **14.7-47.5 months** with targeted therapy. Absolute OS gains: 3-10 months vs control. 5-year OS: 25-40%.	3,924 participants (10 RCTs)	⊕⊕⊕○ MODERATE	OS benefit established in EGFR+ NSCLC, HER2+ gastric, and HCC. Less pronounced in some CRC settings. Heterogeneity in effect size.
Disease Control Rate	**75-92%** with targeted therapies vs 55-70% with chemotherapy.	3,842 participants (12 RCTs)	⊕⊕⊕⊕ HIGH	Includes CR + PR + stable disease. Prolonged disease control characteristic of targeted approaches.
Grade ≥3 Adverse Events	**30-55%** with targeted therapy vs 45-70% with chemotherapy. Profile differs: more diarrhea, rash, less neutropenia/nausea.	5,247 participants (18 studies)	⊕⊕⊕⊕ HIGH	Generally more tolerable than chemotherapy. Specific toxicities manageable with dose modification.

Footnotes: Downgraded one level for inconsistency: OS benefit magnitude varies across cancer subtypes and molecular contexts within endoderm category.

Summary of Findings Table 3: Ectoderm-Derived Cancers - Immune Checkpoint Inhibitors

Population: Patients with advanced ectoderm-derived cancers (melanoma, HNSCC, TNBC, glioblastoma)
Intervention: Anti-PD-1, anti-PD-L1, or anti-CTLA-4 immunotherapy (monotherapy or combination)
Comparison: Chemotherapy, placebo, or other immunotherapy
Setting: Global multicenter trials

Outcome	Anticipated Effects	№ of Participants (Studies)	Certainty (GRADE)	Comments
Objective Response Rate	**Melanoma**: 40-58% (combination ICI), 30-44% (monotherapy). **HNSCC**: 16-36%. **TNBC**: 23% (neoadjuvant setting).	2,456 participants (8 RCTs)	⊕⊕⊕○ MODERATE	Response rates highly variable by disease type and PD-L1 status. Melanoma most responsive.
Progression-Free Survival	**Melanoma**: 11.5 mo (combo) vs 2.9-6.9 mo (control); HR 0.42. **HNSCC**: 5.0 mo vs 3.3 mo. **TNBC**: 9.7 mo vs 5.6 mo (CPS≥10).	3,147 participants (9 RCTs)	⊕⊕⊕⊕ HIGH	PFS benefit consistent across ectodermal cancers, most pronounced in melanoma.
Overall Survival	**Melanoma 10-yr OS**: 43% (combo) vs 19% (ipilimumab). **HNSCC**: 13.6 mo vs 10.4 mo. **TNBC**: NR vs NR (immature).	3,147 participants (9 RCTs)	⊕⊕⊕⊕ HIGH	Unprecedented long-term survival in melanoma establishes potential for cure. OS benefits emerging in other ectodermal cancers.
Durable Response (≥5 years)	**Melanoma**: ~40% of initial responders remain progression-free at 5-10 years.	945 participants (CheckMate 067)	⊕⊕⊕○ MODERATE	Tail of survival curve suggests cure in subset. Long-term data strongest for melanoma.

Grade ≥3 Immune-Related AEs	**Combination ICI**: 55-59%. **Monotherapy**: 15-25%. Most common: colitis, hepatitis, pneumonitis.	4,128 participants (12 studies)	⊕⊕⊕⊕ HIGH	Toxicity profile distinct from chemotherapy. Management algorithms well-established. Permanent discontinuation: 10-15% (combo), 5-7% (mono).

Footnotes: Downgraded one level for inconsistency: ORR varies substantially across ectodermal cancer types; melanoma dramatically higher than other subtypes.
Downgraded one level for indirectness: Long-term durability data primarily from melanoma; less mature in HNSCC and TNBC.

Supplement 7: Conflicts of Interest and Funding Disclosure

Author Contributions and Conflicts of Interest:

D.J. Ferguson (Corresponding Author)

- Role: Conceptualization, methodology, literature search, screening, data extraction, risk of bias assessment, formal analysis, writing - original draft, writing - review & editing
- Conflicts of Interest: None declared
- Funding: No specific funding received for this work

Funding Sources: This systematic review received no specific grant funding from public, commercial, or not-for-profit sectors. The author(s) conducted this work independently.

Acknowledgments: The authors acknowledge the use of Claude 3.5 Sonnet (Anthropic) for preliminary abstract screening prioritization during the systematic review process, as detailed in the Methods section. All final inclusion/exclusion decisions, data extraction, quality assessment, and synthesis were performed exclusively by human reviewers without AI assistance.

End of Supplementary Materials

For access to complete databases including all 5,042 screened records, full data extraction forms for 171 included studies, and additional analyses, please contact the corresponding author.